Φορτώνει......
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease
Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated primarily with analgesics for pain relief. However, elucidation of the multiple pathophysiologic mechanisms leading to vaso-occ...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Blood |
|---|---|
| Κύριος συγγραφέας: | |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society of Hematology
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4760087/ https://ncbi.nlm.nih.gov/pubmed/26758919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-09-618553 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|